Trump's tariffs hit baby industry hard: report
New York, May 8 (UNI) Tariffs on Chinese goods are making it more expensive to raise children in the United States, driving up prices and threatening shortages of critical baby gear at a time when household budgets are already under strain, reported The Washington Post on Wednesday.
"Virtually every car seat, stroller, bassinet and changing table sold in the United States is made in China, making the children's products industry among the most vulnerable to fast-rising costs and shortages," noted the report.
While many industries have taken steps over the years to move manufacturing of clothing, computers and other products to Vietnam, Thailand and India, the baby sector has largely stayed in China, partly due to long-standing ties with factories that meet the U.S. stringent safety requirements, said the report.
More than 70 percent of the baby gear purchased by Americans is manufactured by U.S. companies in China, according to the Juvenile Products Manufacturers Association (JPMA).
"But with new tariffs more than doubling the cost of Chinese imports, prices on baby necessities are rising fast," added the report. "And manufacturers and retailers are suddenly slamming on the brakes, halting months' worth of shipments that economists warn will lead to shortages of strollers, cribs and other necessities as early as this month."
UNI XINHUA GNK
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
38 minutes ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
&w=3840&q=100)
Business Standard
40 minutes ago
- Business Standard
No disruption in operations due to rare earth supply crisis: Maruti
Automaker says situation is 'uncertain and evolving' amid report that it has made e-Vitara production cuts Deepak Patel New Delhi Maruti Suzuki India (MSIL) said on Thursday its operations are unaffected by the global rare earth magnet shortage, but added that the situation is 'uncertain and evolving'. The company said it is exploring multiple solutions to maintain continuity in operations and will notify stakeholders if any material impact arises. The clarification comes amid a Reuters report earlier this week stating that the country's largest carmaker has slashed production estimates for its upcoming electric SUV, the e-Vitara, by nearly two-thirds due to rare earth supply constraints. According to the report, MSIL has revised its production target for the e-Vitara from 26,000 units to just 8,200 units for the first half of FY26. The report, citing internal documents, attributed the change to 'supply constraints' of critical rare earth elements, particularly magnets used in electric powertrains. Despite the scale back, MSIL reportedly aims to meet its full-year target of 67,000 units by ramping up production in the second half of the financial year. 'Regarding the situation on rare earth, as of now there is no disruption in our operation due to this issue,' said a MSIL spokesperson, in a statement on Thursday. 'There is a lot of uncertainty and the situation is continuously evolving. We are monitoring the situation and pursuing multiple solutions to ensure continuity in our operations. If and when there is any material impact to our business, we will inform all stakeholders in line with regulatory requirements,' the spokesperson added. Rare earth magnets are a crucial component in electric vehicle (EV) motors and are also used in power steering systems, speakers, and other car components. Their shortage stems from China's decision in April to tighten export controls on key rare earth elements, including neodymium, dysprosium and terbium. These elements are essential in the production of permanent magnets used in EVs. According to the Federation of Automobile Dealers Associations (FADA), electric car sales in India reached 107,645 units in fiscal year 2024–25, up from 91,506 units in FY24, marking a 17.7 per cent year-over-year increase. China controls more than 90 per cent of the global rare earth magnet supply chain. China's new export rules require companies to obtain end-use certifications and licences, which has slowed shipments and created uncertainty for automakers worldwide. The disruption has raised alarm in India's automotive industry, especially among EV manufacturers who depend heavily on Chinese supplies. The Indian government is monitoring the situation. A delegation may soon travel to China to expedite clearances for shipments stuck due to regulatory bottlenecks. Additionally, the government is evaluating measures such as incentivising domestic rare earth magnet production and expanding recycling initiatives. The rare earth crunch comes at a time when Indian automakers are stepping up EV production to meet future emission targets and global demand.
Time of India
40 minutes ago
- Time of India
Rare earth magnets: Maruti Suzuki explores multiple options to ensure operational continuity
Maruti Suzuki India on Thursday said it is exploring multiple solutions to ensure continuity in its manufacturing operations amid the ongoing rare earth magnet shortage issue. The country's largest carmaker noted that there is a lot of uncertainty due to the situation, but so far, there is no impact on its manufacturing activities. "Regarding the situation on rare earth, as of now there is no disruption in our operation due to this issue. There is a lot of uncertainty and the situation is continuously evolving," the car market leader said in a statement. It further said, "We are monitoring the situation and pursuing multiple solutions to ensure continuity in our operations." If and when there is any material impact to the company's business, the automaker will inform all stakeholders in line with regulatory requirements, Maruti Suzuki India stated. Live Events MORE STORIES FOR YOU ✕ Rare earths roadblock: India's automakers await China's nod for magnet talks Rare earths are not rare: Chinese move can backfire US, China reach deal to ease rare earths export curbs, keep tariff truce alive « Back to recommendation stories I don't want to see these stories because They are not relevant to me They disrupt the reading flow Others SUBMIT Domestic auto industry is forced to take steps as the Chinese government has put restrictions since April 4 on the export of rare earth elements and related magnets. China has mandated special export licences for seven rare earth elements and related magnets. The country controls over 90 per cent of global processing capacity for the magnets, used across sectors including automobiles, home appliances and clean energy. With no clarity on approvals, the Indian automobile industry is staring at production issues, especially for electric vehicles . The domestic automobile industry has also sought government support in expediting approvals from the Chinese government for importing rare earth magnets . The critical materials include samarium, gadolinium, terbium, dysprosium and lutetium, which are essential in electric motors, braking systems, smartphones and missile technology. Rare earth magnets are integral to permanent magnet synchronous motors (PMSMs) used in EVs for their high torque, energy efficiency and compact size. Hybrids also depend on them for efficient propulsion. In internal combustion engine (ICE) vehicles, the use of rare earth magnets is largely limited to electric power steering and other motorised systems.
